What is CAH's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for CAH.

Stock Ratings / Health Care / CAH / options

COR (72) MCK (85) HLF (64) NUS (50) ⌘ Pro Terminal →

Cardinal Health Inc. (CAH) Options Positioning, Max Pain & Unusual Sweeps

$254.33 +1.54% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $255.65

Cardinal Health Inc. (CAH) earns a Roarable Rating of B (Buy) with 73/100 RQD Confidence. High-quality cash engine (4% profit margin, 30% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

ROARABLE B • BUY Cap $58.00B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CAH Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is CAH stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Cardinal Health Inc. (NYSE: CAH) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 73/100 at a spot price of $254.33 (+1.54% 1D, market cap $58.00B). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 17/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 14/20. Across 1016 tracked Health Care issuers, CAH ranks #45 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does CAH compare to COR and MCK in the Health Care sector?

▼

Within the Health Care sector (Other Pharmaceuticals), CAH carries a Roarable B (73/100 RQD), trailing P/E of 37.2x, gross margin of 3.7%, and ROIC of 29.7%. By comparison, COR (Cencora Inc.) holds a B grade (72/100 RQD, P/E 40.6x, ROIC 26.8%, cap $63.13B) and MCK (McKesson Corporation) posts a A- grade (85/100 RQD, P/E 24.0x, ROIC 38.6%, cap $115.96B). Among the 5-stock peer group, HLF leads on earnings multiple (5.9x) while MCK leads on capital efficiency (38.6% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CAH?

▼

Per CAH's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0000721371), Cardinal Health Inc. generated $222.58B in revenue (-1.9% YoY), $1.56B in net income, and $1.85B in free cash flow against $58.08B in total assets and $13.59B in total debt. Key quantitative strengths: Strong cash generator (4% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $255.65 (+0.52%)🧬 Cannibal Buyback (-1.80% YoY Shares)⚙️ Cash Engine: 16/20 (B+) • 0.8% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 73/100 (B) historically ranked in the Top 13% of excess returns over the next 90 days (+7.1% avg 90D alpha vs SPY • 69.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERBUY • B

3-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw B+ · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE+6.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CAH)Realized 20D OHLCV Swing Band: ±4.8%

Deterministic 5-Pillar Attribution (73/100 Composite)

🔍 WHY CAH SCORES 73/100 (B) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+17/20 pts (23% of score)

20D Institutional Volume Accumulation (±4.8% realized swing band)

▲ #2 Bullish Driver: Cash Engine Quality+16/20 pts (22% of score)

SEC XBRL FY 2025 (10-K): 0.8% FCF Margin ($1.85B FCF) & 3.7% Gross Margin

▼ #1 Drag / Risk Factor: Macro Regime Fit12/20 pts (-8 pt drag)

Macro rate sensitivity & RSI-14 (58.1) create a -8 pt regime headwind

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C+$247.74+3.9% Next Q

Q2 (-2Q)

Grade B-$257.46-4.9% Next Q

Q3 (-1Q)

Grade B$244.76+3.9% Next Q

Current

Grade B$254.33+7.1% Hist 90D α

Trajectory: C+ (65) → B (73)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the CAH Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 73/100 (B) score, CAH faces multiple-compression risk if 37.2x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-1.80% YoY Shares) — any gross margin slip below 15.0% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($238.83) or 200D SMA ($222.74) invalidates the momentum regime and cuts Target Base ($271.50) toward Bear Floor ($208.55).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CAH• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “CAH Beats Next Quarter EPS Consensus (Dec 28, 2026) & Holds Above 200D SMA”

YES 73%NO 27%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±4.8%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (CAH)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for CAH.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Options & Swing Structure Desk

Whale Flow & Momentum Playbook: Evaluating CAH & AI Leaders Without Chasing Tops

✓Institutional whale strikes & implied earnings move audit on CAH
✓How disciplined traders manage risk using pre-published trigger & invalidation levels
✓Includes nightly RQD rating-change & forensic signal email alerts on tracked leaders

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

CAH // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +29.06%⚡ TESTING RESISTANCE

2026-11-03O $251.1H $254.3L $250.5C $254.3VOL 1.95M

RES: $259.9SUP: $214.7SMA50: $238.8SMA200: $222.7

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CAH Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CAH Butterfly Map → + Track CAH →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

28.5%/yr Implied 5Y Growth

vs. -1.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on CAH today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CAH. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CAH today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CAH)

Health Care Rank #45 of 1016 ⚔️ COR vs CAH Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CAH vs. COR, MCK, HLF, NUS)

Industry: Other Pharmaceuticals (10 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Cardinal Health Inc. (CAH) ranks #45 by composite RQD confidence (73/100, grade B) and #34 by equity capitalization ($58.00B). Within this direct 5-issuer industry benchmark cohort, HLF leads on earnings valuation at 5.9x trailing P/E, while MCK leads on capital efficiency and profitability with 38.6% ROIC and 3.6% gross margin. MCK currently holds the highest overall quantitative score in the immediate peer group at 85/100 (A-) compared with CAH at 73/100 (B).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
CAH ACTIVE Cardinal Health Inc.	B	73/100	37.2x	3.7%	29.7%	+1.54%	$58.00B	Benchmark Subject
COR Cencora Inc.	B	72/100	40.6x	3.6%	26.8%	+2.12%	$63.13B	/cor-vs-cah →
MCK McKesson Corporation	A-	85/100	24.0x	3.6%	38.6%	+0.38%	$115.96B	/mck-vs-cah →
HLF Herbalife Ltd.	C	64/100	5.9x	77.9%	34.4%	+1.76%	$1.37B	/hlf-vs-cah →
NUS Nu Skin Enterprises Inc.	D	50/100	—	69.4%	6.7%	+2.80%	$226.3M	/nus-vs-cah →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-06-30 • CIK 0000721371

In its most recent audited fiscal period (FY2025, filed 2025-06-30), Cardinal Health Inc. (CAH) reported GAAP revenue of $222.58B (-1.9% vs. FY2024 revenue of $226.83B , and +8.6% cumulative change since FY2023) , GAAP net income of $1.56B, operating cash flow of $2.40B, and free cash flow of $1.85B (-43.1% YoY). On the balance sheet, CAH closed FY2025 with $58.08B in total assets against $13.59B in total debt (Altman Z-Score: 5.16, Piotroski F-Score: 6/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-06-30	$222.58B	$1.56B	$2.40B	$1.85B	$58.08B	$13.59B
FY2024 (FY)	2024-06-30	$226.83B	$852.0M	$3.76B	$3.25B	$47.00B	$11.00B
FY2023 (FY)	2023-06-30	$204.98B	$330.0M	$2.84B	-$6.38B	$245.97B	$57.56B

3. CAH Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CAH stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does CAH compare to COR and MCK in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for CAH?

Where is CAH trading relative to its 50-day, 200-day, and 52-week technical levels?

CAH last traded at $254.33 (+1.54% on volume of 1,895,118 shares), positioning the stock +6.49% above its 50-day simple moving average ($238.83) and +14.18% above its 200-day simple moving average ($222.74). Across its 52-week range of $180.45 to $259.84, CAH sits at the 93.1% percentile with a 14-day RSI of 58.1 (BULLISH MOMENTUM) and an implied next-earnings move of ±4.8% ($242.12 to $266.54).

Direct Sub-Reports: CAH RQD Cockpit CAH 12M Forecast CAH Earnings & Move CAH Dividends & DRIP CAH Insiders & 13F CAH Whale Options CAH Profit Sankey CAH News & Why

ROARABLE RATING BRIEF • RQD 73/100 (B) ✓ SEC XBRL & RQD VERIFIED

CAH — Cardinal Health Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-06-30

1. Roarable Rating Brief: What This Means to a Prospective Investor

Cardinal Health Inc. (CAH) earns a live Roarable RQD composite score of 73/100, corresponding to a B letter grade (Roarable Buy) at a spot price of $254.33 (+1.54% 1D, market capitalization $58.00B).

Fundamental Cash Engine (16/20): Anchored by return on invested capital (ROIC) of 29.7%, gross margin of 3.7%, operating margin of 1.0%, and free cash flow yield of 3.18%.
Whale 13F & Options Flow (17/20) + Insider Conviction (14/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (12/20) + Forensic Balance Sheet (14/20): Incorporates a 0.90x equity beta, Altman Z-Score of 5.16, Piotroski F-Score of 6/9, and Debt/Equity of 0.85x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Cardinal Health Inc. Is a NYSE-listed issuer in the Health Care sector, within the Other Pharmaceuticals industry..1B. The profile does not itemize products, customer segments, or revenue model. Per the Market Data, gross margin is 3.7%, operating margin is 1%, and net margin is 0.7%, which indicates a low-margin operating structure.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-06-30), Cardinal Health Inc. (CAH) reported $222.58B in annual revenue (up from $226.83B in FY2024, -1.9% YoY) and $1.56B in GAAP net income. Over the multi-year SEC filing window from FY2023 ($204.98B revenue, $330.0M net income) through FY2025, CAH scaled operating cash flow to $2.40B and free cash flow to $1.85B, backed by $58.08B in total assets against $13.59B in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (B • RQD 73/100): Strong cash generator (4% profit margin)—profits are backed by real money, not accounting tricks. Big institutional funds and options desks are actively positioning on the bullish side. With Fundamental Cash Engine at 16/20 and Institutional Whale Flow at 17/20, sustained execution supports upside toward the upper end of the $180.45 – $259.84 52-week range.
🐻 Primary Bear Case & Valuation Risk: Broader market pullbacks can still drag down strong stocks in the short run. Investors must weigh 37.2x trailing P/E and 24.5x EV/EBITDA against 1.0% operating margins and a 0.90x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies are — Sector correlations are — beyond the sector and industry classification (Health Care / Other Pharmaceuticals). Second-order bottlenecks are — The only related reference from the news wire is the "medical distribution challenges in Q1" headline, which the source does not elaborate on.

Key Question #1: Can CAH sustain or expand its 1.0% operating margin and 29.7% ROIC against Other Pharmaceuticals peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $222.58B and free cash flow of $1.85B, how will capital allocation balance growth reinvestment against $13.59B in total debt?
Key Question #3: How sensitive is CAH's 34.6x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 0.90x)?

CAH Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Cardinal Health Inc. (CAH) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to CAH Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 21h ago

Should Value Investors Buy Cardinal Health (CAH) Stock?

Yahoo Finance report covering Cardinal Health Inc. (CAH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investor's Business Daily • 1d ago

IBD Stock Of The Day Tests New Buy Point As Indicators Suggest More Upside

Investor's Business Daily report covering Cardinal Health Inc. (CAH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Cardinal Health (CAH) Laps the Stock Market: Here's Why

Yahoo Finance report covering Cardinal Health Inc. (CAH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE The Globe and Mail • 1d ago

RBC Capital Sticks to Its Buy Rating for Cardinal Health (CAH)

The Globe and Mail report covering Cardinal Health Inc. (CAH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Reasons to Retain Cardinal Health Stock in Your Portfolio for Now

Yahoo Finance report covering Cardinal Health Inc. (CAH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE The Globe and Mail • 1d ago

Can CAH's Specialty Strength Offset Medical Distribution Challenges in Q1?

The Globe and Mail report covering Cardinal Health Inc. (CAH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Are Medical Stocks Lagging Cardinal Health (CAH) This Year?

Yahoo Finance report covering Cardinal Health Inc. (CAH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Yahoo • 20h ago

AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy for 2027?

AbbVie boasts faster revenue growth and stronger cash generation, while Bristol Myers trades at half the valuation multiple, a classic growth-versus-value showdown.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

CAH Bull vs. Bear Conversation Board — What's Your Call at $254.33?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CAH 🐻 33% BEARISH CONVICTION

MA MacroHawk_NYC RQD DEBATE OPENER • Cross-Asset Macro Desk 🐂 BULLISH 🎯 Target: $293.06 (+17.0%)

📌 Pinned Debate

Per the Roarable RQD rating, a 29.7% ROIC and 16/20 cash-engine pillar, paired with a 5.16 Altman Z-Score, point to capital-efficient r

The street is overcomplicating Cardinal Health Inc. (CAH). Per the Roarable RQD rating, a 29.7% ROIC and 16/20 cash-engine pillar, paired with a 5.16 Altman Z-Score, point to capital-efficient returns and a sound balance sheet.. With an RQD score of 73/100 (B) and Forensic Balance Sheet at 14/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $270.52.

VolSurface_Trader 🐂 BULL

@RiskArb_Desk Shorting a 17/20 institutional whale-flow stock at $250.48 is dangerous when funds are rotating into Health Care.

RI RiskArb_Desk RQD DEBATE OPENER • Hedged Event Driven 🐻 BEARISH 🎯 Target: $200.38 (-20.0%)

Spot @ $250.48

Per the Market Data, a 0.7% net margin and 37.2 trailing P/E leave little earnings cushion against a valuation that already prices in s

Careful chasing CAH at $250.48. Per the Market Data, a 0.7% net margin and 37.2 trailing P/E leave little earnings cushion against a valuation that already prices in substantial expectations.. Gross margin is 3.7%, but operating margin is 1.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $200.38 on multiple compression.